Revvity (RVTY) Reports Strong Second Quarter 2025 Results, Outperforms Expectations
Revvity has reported strong financial results for Q2 2025, surpassing expectations with a revenue of $720 million.
BTC$64,354.00-0.93%
ETH$1,875.11-2.02%
USDT$0.9993+0.02%
USDC$0.9999+0.00%
XRP$1.11-0.37%
SOL$76.11-1.64%
TRX$0.3231-0.31%
FIGR_HELOC$1.04-0.04%
HYPE$64.20-4.62%
DOGE$0.0733-0.39%
USDS$0.9998+0.00%
ZEC$553.68-3.33%
RAIN$0.0139-3.98%
LEO$9.83+0.14%
WBT$56.26-1.04%
BTC$64,354.00-0.93%
ETH$1,875.11-2.02%
USDT$0.9993+0.02%
USDC$0.9999+0.00%
XRP$1.11-0.37%
SOL$76.11-1.64%
TRX$0.3231-0.31%
FIGR_HELOC$1.04-0.04%
HYPE$64.20-4.62%
DOGE$0.0733-0.39%
USDS$0.9998+0.00%
ZEC$553.68-3.33%
RAIN$0.0139-3.98%
LEO$9.83+0.14%
WBT$56.26-1.04%
Bank of Hawai‘i Corporation reported a successful second quarter in 2025 with $129.7 in net interest income.
Revvity has reported strong financial results for Q2 2025, surpassing expectations with a revenue of $720 million.
As Intel advances its restructuring efforts, market volatility and noisy stock signals are to be expected.
Charter Communications reported a slight increase in Q2 2025 revenue, driven by mobile and Internet services, while video and advertising sales declined.
Aon plc reported strong second quarter results for 2025, with significant revenue growth and improved operating income.
Centene Corporation's Q2 2025 results revealed a loss per share and revenue figures that diverged from expectations.
Nasdaq's second quarter of 2025 demonstrated strong financial results with a net revenue increase of 13% compared to the previous year, surpassing expectations.
Blackstone's Q2 2025 results exceeded expectations with significant earnings growth.
Honeywell's Q2 2025 results exceeded expectations with sales and EPS surpassing forecasts.
Exposure to Lockheed Martin represents exposure to U.S. hegemony maintenance.
AT&T's second-quarter results have exceeded expectations, driven by robust growth in 5G and fiber subscribers.
Boston Scientific's Q2 2025 results exceeded expectations, with net sales of $5.061 billion and adjusted EPS of $0.75.
Thermo Fisher Scientific's second quarter of 2025 demonstrated a 3% revenue increase to $10.85 billion, slightly surpassing expectations.